Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1517-1525

  Comer, Jason E ^a   Ray, Bryan D ^a   Henning, Lisa N ^a   Stark, Gregory V ^a   Barnewall, Roy E ^a   Mott, Jason M ^a   Meister, Gabriel T ^a  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; C REACTIVE PROTEIN; MONOCLONAL ANTIBODY; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

AEROSOL; AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY BLOOD LEVEL; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; BODY TEMPERATURE MEASUREMENT; BODY TEMPERATURE MONITORING; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; FEMALE; HEMATOLOGICAL PARAMETERS; IMMUNITY; LD 50; MALE; NEW ZEALAND WHITE RABBIT; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN BLOOD LEVEL; PROVOCATION TEST; SIGNIFICANT INCREASE IN BODY TEMPERATURE; TREATMENT RESPONSE;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOLOGICAL MARKERS; BLOOD CELLS; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; FEMALE; FEVER; IMMUNOTHERAPY; MALE; RABBITS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84865965159     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00292-12     Document Type: Article

References (32)

1. Ascenzi P, et al. 2002. Anthrax toxin: a tripartite lethal combination. FEBS Lett. 531:384-388. (Pubitemid 35336056)
2. Boyer AE, et al. 2009. Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques. Infect. Immun. 77:3432-3441.
3. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N. Engl. J. Med. 341:815-826. (Pubitemid 29420478)
4. Dragan AI, Albrecht MT, Pavlovic R, Keane-Myers AM, Geddes CD. 2012. Ultra-fast pg/ml anthrax toxin (protective antigen) detection assay based on microwave-accelerated metal-enhanced fluorescence. Anal. Biochem. 425:54-61.
5. Duesbery NS, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737. (Pubitemid 28243347)
6. Fritz DL, et al. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Invest. 73:691-702.
7. Huan TN, Ganesh T, Han SH, Yoon MY, Chung H. 2011. Sensitive detection of an anthrax biomarker using a glassy carbon electrode with a consecutively immobilized layer of polyaniline/carbon nanotube/peptide. Biosens. Bioelectron. 26:4227-4230.
8. Human Genome Sciences, Inc. 2009. U.S. FDA Anti-Infectives Advisory Committee meeting briefing document. Raxibacumab: treatment of inhalation anthrax. BLA 125349. Human Genome Sciences, Inc., Rockville, MD.
9. Jernigan DB, et al. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028. (Pubitemid 35256987)
10. Jernigan JA, et al. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.
11. Kobiler D, et al. 2002. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:544-560.
12. Kobiler D, et al. 2006. Protective antigen as a correlative marker for anthrax in animal models. Infect. Immun. 74:5871-5876. (Pubitemid 44484574)
13. Lawrence WS, et al. 2009. The physiologic responses of Dutch belted rabbits infected with inhalational anthrax. Comp. Med. 59:257-265.
14. Leppla SH. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166. (Pubitemid 12008374)
15. Little SF, et al. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430. (Pubitemid 37510273)
16. Migone TS, et al. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361:135-144.
17. Mikesell P, Ivins BE, Ristroph JD, Dreier TM. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376. (Pubitemid 13212538)
18. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612. (Pubitemid 24260471)
19. Mohamed N, et al. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73:795-802. (Pubitemid 40165735)
20. Mohamed N, et al. 2004. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 72:3276-3283. (Pubitemid 38697749)
21. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. 1999. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNFα. FEBS Lett. 462:199-204.
22. Peterson JW, et al. 2007. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun. 75:3414-3424. (Pubitemid 47040942)
23. Peterson JW, et al. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 74:1016-1024. (Pubitemid 43185538)
24. Rossi CA, et al. 2008. Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax. Infect. Immun. 76:5790-5801.
25. Sawada-Hirai R, et al. 2004. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines 2:5.
26. Suffin SC, Carnes WH, Kaufmann AF. 1978. Inhalation anthrax in a home craftsman. Hum. Pathol. 9:594-597. (Pubitemid 9079119)
27. Twenhafel NA. 2010. Pathology of inhalational anthrax animal models. Vet. Pathol. 47:819-830.
28. Vasconcelos D, et al. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 83:1201-1209. (Pubitemid 37013055)
29. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352:739-745. (Pubitemid 32015030)
30. Wang F, et al. 2004. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum. Antibodies 13:105-110. (Pubitemid 40202531)
31. Yee SB, Hatkin JM, Dyer DN, Orr SA, Pitt ML. 2010. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment. Comp. Med. 60:461-468.
32. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992. (Pubitemid 28521045)